Compositions for the treatment of sarcopenia or disuse atrophy

Patent metadata

Field	Value
Publication number	US-12496328-B2
Application number	US-201917261314-A
Country	US
Kind code	B2
Filing date	Jul 19, 2019
Priority date	Jul 20, 2018
Publication date	Dec 16, 2025
Grant date	Dec 16, 2025

Abstract

The present invention relates to a substance that activates the GDF5 pathway, for use in a method for the treatment of age-related sarcopenia or disuse atrophy.

First claim

The invention claimed is:

1 . A method for the treatment or prevention of sarcopenia or disuse atrophy in a subject, the method comprising administering to the subject a substance selected from the group consisting of a synthetic or recombinant GDF5 protein, a GDF5 peptide and a vector encoding GDF5.

2 . A method for treating or preventing muscle weakness in Duchenne muscular dystrophy or amyotrophic lateral sclerosis in a subject, the method comprising administering to the subject a substance selected from the group consisting of a synthetic or recombinant GDF5 protein, a GDF5 peptide and a vector encoding GDF5, alone or in combination with a treatment of Duchenne muscular dystrophy or amyotrophic lateral sclerosis.

3 . The method according to claim 1 , wherein the substance is recombinant human GDF5.

4 . The method according to claim 1 , wherein the subject is aged 50 years or older.

5 . The method according to claim 1 , wherein the substance is administered via the oral, nasal, intravascular, intramuscular, intraperitoneal route, transdermal or subcutaneous route.

6 . The method according to claim 1 , wherein the substance is administered on a monthly basis, a weekly basis, or a daily basis.

7 . The method according to claim 1 , wherein the treatment of sarcopenia results in an increase of muscle mass and/or function, an increase in physical performance or mobility, and/or an increase in muscle strength.

8 . The method according to claim 1 , comprising administering to the subject a pharmaceutical composition comprising the substance selected from the group consisting of a synthetic or recombinant GDF5 protein, a GDF5 peptide and a vector encoding GDF5 and a pharmaceutically acceptable carrier.

9 . The method according to claim 8 , wherein the substance is recombinant human GDF5.

10 . The method according to claim 2 , wherein the substance is recombinant human GDF5.

11 . The method according to claim 2 , wherein the substance is administered via the oral, nasal, intravascular, intramuscular, intraperitoneal route, transdermal or subcutaneous route.

12 . The method according to claim 2 , wherein the substance is administered on a monthly basis, a weekly basis, or a daily basis.

13 . The method according to claim 2 , comprising administering to the subject a pharmaceutical composition comprising the substance selected from the group consisting of a synthetic or recombinant GDF5 protein, a GDF5 peptide and a vector encoding GDF5 and a pharmaceutical acceptable carrier.

14 . The method according to claim 13 , wherein the substance is recombinant human GDF5.

Assignees

• Association Inst De Myologie
• Inst Nat Sante Rech Med
• Univ Sorbonne

Inventors

• Pietri-Rouxel France
• Falcone Sestina

Classifications

• A61K38/1875

  Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor · CPC title

• G01N2800/2878

  Muscular dystrophy · CPC title

• G01N2333/475

  Assays involving growth factors · CPC title

• G01N33/74

  involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors} · CPC title

• A61K38/177

  Receptors; Cell surface antigens; Cell surface determinants · CPC title